DAWNRAYS PHARMACEUTICAL HLDGS financial statements, including revenue, expenses, profit, and loss
The total revenue of 2348 for the last semiannual is 541.49 M HKD, and it's 26.33% lower compared to the previous semiannual. The net income of H2 23 is 75.69 M HKD.